Immune Responses to Middle East Respiratory Syndrome Coronavirus during the Acute and Convalescent Phases of Human Infection

Clinical Infectious Diseases

Volumn 68, Issue 6, 2019, Pages 984-992

  Shin, Hyoung Shik ^a   Kim, Yeonjae ^a   Kim, Gayeon ^a   Lee, Ji Yeon ^b   Jeong, Ina ^b   Joh, Joon Sung ^b   Kim, Hana ^c   Chang, Eunjin ^c   Sim, Soo Yeon ^c   Park, Jun Sun ^c   Lim, Dong Gyun ^c  

^a Department of Internal Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c National Medical Center   (South Korea)

Author keywords

acute phase of infection; immune response; MERS coronavirus; T lymphocytes

Indexed keywords

E PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; M PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRAL S PROTEIN; CYTOKINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ARTIFICIAL VENTILATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONVALESCENCE; COUGHING; DISEASE SEVERITY; FEVER; HEADACHE; HOSPITAL PATIENT; HUMAN; IMMUNE RESPONSE; MALAISE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SOUTH KOREA; AGED; CORONAVIRUS INFECTION; FEMALE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; CYTOKINES; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; PATIENT OUTCOME ASSESSMENT; REPUBLIC OF KOREA; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 85062405648     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy595     Document Type: Article

References (35)

1. Fehr AR, Channappanavar R, Perlman S. Middle East respiratory syndrome: emergence of a pathogenic human coronavirus. Annu Rev Med 2017; 68:387–99.
2. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386:995–1007.
3. Park WB, Perera RA, Choe PG, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis 2015; 21:2186–9.
4. Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 2016; 62:477–83.
5. Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One 2014; 9:e88716.
6. Guan WD, Mok CK, Chen ZL, et al. Characteristics of traveler with Middle East respiratory syndrome, China, 2015. Emerg Infect Dis 2015; 21:2278–80.
7. Kim ES, Choe PG, Park WB, et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci 2016; 31:1717–25.
8. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016; 6:25359.
9. Zhao J, Alshukairi AN, Baharoon SA, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses. Sci Immunol 2017; 2:eaan5393.
10. Yu P, Xu Y, Deng W, et al. Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus. PLoS One 2017; 12:e0172093.
11. Niemeyer D, Zillinger T, Muth D, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 2013; 87:12489–95.
12. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 2014; 111:4970–5.
13. Zhao J, Zhao J, Mangalam AK, et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 2016; 44:1379–91.
14. Baseler LJ, Falzarano D, Scott DP, et al. An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity. Am J Pathol 2016; 186:630–8.
15. Li CK, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol 2008; 181:5490–500.
16. Perera RA, Wang P, Gomaa MR, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 2013; 18. pii:20574.
17. Kim Y, Cheon S, Min CK, et al. Spread of mutant Middle East respiratory syndrome coronavirus with reduced affinity to human CD26 during the South Korean outbreak. MBio 2016; 7:e00019.
18. Alsahafi AJ, Cheng AC. The epidemiology of Middle East respiratory syndrome coronavirus in the kingdom of Saudi Arabia, 2012–2015. Int J Infect Dis 2016; 45:1–4.
19. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752–61.
20. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247–58.
21. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313–7.
22. Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 2016; 186:652–8.
23. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998; 391:908–11.
24. Coleman CM, Sisk JM, Halasz G, et al. CD8+ T cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome. J Virol 2016; 91. pii:e01825-16.
25. Moskophidis D, Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 1998; 188:223–32.
26. Hu Z, Molloy MJ, Usherwood EJ. CD4(+) T-cell dependence of primary CD8(+) T-cell response against vaccinia virus depends upon route of infection and viral dose. Cell Mol Immunol 2016; 13:82–93.
27. Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998; 188:1705–15.
28. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severeacuterespiratorysyndrome:retrospectiveanalysis.BMJ2003;326:1358–62.
29. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95–103.
30. Chen H, Hou J, Jiang X, et al. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol 2005; 175:591–8.
31. Peng H, Yang LT, Wang LY, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 2006; 351:466–75.
32. Yang L, Peng H, Zhu Z, et al. Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. J Gen Virol 2007; 88:2740–8.
33. Chan PK, Ma S, Ngai SM. Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods. Hong Kong Med J 2011; 17:S26–30.
34. Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol 2011; 186:7264–8.
35. Ng OW, Chia A, Tan AT, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine 2016; 34:2008–14.